Most Recent Annual Report
Upgrade your company profile to unlock all of your annual report content on AnnualReports.com
2019 Form 10K, 2020 Annual Report

Upgrade your company profile to unlock all of your annual report content on AnnualReports.com
Work for Myovant Sciences Ltd.?
Claim Your ProfileUpgrade your company profile to unlock all of your annual report content on AnnualReports.com
Upgrade your company profile to unlock all of your annual report content on AnnualReports.com
Myovant Sciences aspires to be the leading healthcare company focused on redefining care for women and for men. The company’s lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. The company has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction. Takeda Pharmaceuticals International AG, a subsidiary of Takeda Pharmaceutical Company Limited, the originator of relugolix, previously granted the company a worldwide license to develop and commercialize relugolix (excluding Japan and certain other Asian countries) and an exclusive license to develop and commercialize MVT-602 in all countries worldwide. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is the majority shareholder of Myovant.